Category Archives: Siegall

The Role of Clay B. Siegall in Improving Quality of Treatment that Cancer Patients Receive

Clay B. Siegall is the chief executive officer of Seattle Genetics, a top biotechnology firm that he started in 1998. Siegall studied zoology at the acclaimed University of Maryland and later Ph.D. in genetics at the George Washington University. His background in science has enabled him to run activities at Seattle Genetics, a company that specializes in cancer research. For years, Dr. Siegall has contributed immensely to the field of biotechnology. Throughout his career, he has written and published over 70 research papers. Before working at Seattle Genetics, Dr. Siegall worked with National Institute of Health for three years and later at Bristol-Myers Squibb Pharmaceuticals Research Institute. In 1998, he decided to establish his biotechnology firm (Seattle Genetics.

Drugs manufactured by Seattle Genetics

Early in his career at Seattle Genetics, Dr. Siegall participated in the development of antibody-drug conjugates (ADC) used to treat cancer. Seattle Genetics prides itself to be the company that pioneered this technology that can target cancer cells and kill them. One of the top drugs developed by this company is Adcetris. This drug has been proved to treat various forms of lymphomas such as Hodgkin lymphoma and anaplastic large cell lymphoma. Another drug in the process of being commercialized is 33A, which is used to treat acute myeloid leukemia. According to Dr. Siegall, the drug is in phase 3 of clinical trials and will soon be approved by FDA. Dr. Siegall leadership has earned the company millions of dollars through licensing deals with organizations such as GlaxoSmithKline, Genentech, and Pfizer.

Other ventures

Dr. Siegall also works with Alder Biopharmaceuticals Inc. – he serves as the director of the board that governs the company. Alder Biopharmaceuticals Inc. manufactures antibody therapeutics through various novel technologies. Drugs produced by this company are meant for patients suffering from autoimmune diseases and inflammatory diseases. He also works in closely with other companies such as Mirna Therapeutics, Inc. and Ultragenyx Pharmaceuticals. These two companies also participate in the manufacturing of drugs to cure cancer. Appointment of Dr. Siegall to head these companies is due to his interest and experience in cancer research.